Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

NCT02325791 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1177

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: Suptavumab 30 mg/kg
DRUG: Placebo Matched to Suptavumab
DRUG: Suptavumab 30 mg/kg- 1 Dose
DRUG: Suptavumab 30 mg/kg - 2 Doses

Sponsor

Regeneron Pharmaceuticals